iShares Biotechnology ETF (NQ:IBB)

210.00 +1.31 (+0.63%)

Delayed Quote Updated: 11:15 AM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

28 29 Next >

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

How To Prepare For Monday By Watching Trading Range Lows ↗

April 24, 2022

After both the Russell 2000 and the Nasdaq 100 failed to hold or clear over the 50-Day moving average, the bleeding has not stopped. Now that IWM and many key ETFs are near the bottom of their trading...

Via Talk Markets

The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial ↗

April 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Pfizer: What Comes After the Covid-19 Fire? ↗

April 21, 2022

Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles.

Via InvestorPlace

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗

April 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Does the Nasdaq 100 Index Have a Chokehold on the Stock Market? ↗

April 20, 2022

Wednesday, the stock market stuck with its choppy trend.

Via Talk Markets

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study ↗

April 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Real Motion Shows Hidden Momentum in the Russell 2000 and S&P 500 ↗

April 19, 2022

While the market is choppy and traders should be extra careful, if Wednesday shows follow-through in both price and momentum, we can watch for Tuesday’s rally to continue.

Via Talk Markets

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗

April 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗

April 17, 2022

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...

Via Benzinga

Will the Market Pick a Direction On Monday? ↗

April 14, 2022

When the indices are tough to read, it can help to watch other symbols like JNK and VXX.

Via Talk Markets

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Why We Bought Invesco Agricultural Fund (DBA) ↗

April 12, 2022

One problem with soft commodities is when countries need more food, there is no instant fix, as it takes time to grow. Along with drought and other potential issues, it could take another 2 to 3 years...

Via Talk Markets

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks ↗

April 08, 2022

Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.

Via InvestorPlace

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More ↗

April 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space ↗

April 06, 2022

If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher.

Via Talk Markets

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Regional Banking (KRE) Holds onto Support and Momentum ↗

April 04, 2022

If the regional banking space can make a quick turnaround Silvergate Capital could be one company that leads the way higher.

Via Talk Markets

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

If The Market Holds Watch Bitcoin And The Biotech Space ↗

April 03, 2022

The past week was a chop fest in the major indices with large intraday price swings. While the 3 major indices closed roughly flat on Friday, the Russell 2000 made a late-day turnaround ending up over...

Via Talk Markets

March Madness, Revisiting The First Quarter ↗

April 03, 2022

You might be surprised to learn that betting on March Madness this year topped $3.1 billion. That number only covers the legitimate bracket contests and betting. I am confident that it is much higher...

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.